



15  
17.


Metabolites of Ecetinasidin 743 formed by human cytochrome CYP3A4, said metabolites being selected from the group consisting of:



ETM 305



ETM 204



ETM 775

16  
18.

The Ecetinasidin 743 metabolite of Claim 17, designated herein as ETM-305.

17  
19.

The Ecetinasidin 743 metabolite of Claim 17, designated herein as ETM-204.

18  
20.

A pharmaceutical composition comprising one or more of the Ecetinasidin 743 metabolites of Claim 17 and a pharmaceutically acceptable diluent, excipient or carrier.


19  
21.

The pharmaceutical composition of Claim 20, wherein the


Ecteinascin 743 metabolite is designated herein as ETM-305.

<sup>20</sup>  
~~22~~. The pharmaceutical composition of Claim 20, wherein the Ecteinascin 743 metabolite is designated herein as ETM-204.


<sup>21</sup>  
~~23~~. A method of treating mammalian leukemia in patients in need of such treatment, said method comprising administering an effective amount of a metabolite of Ecteinascin 743 formed by human cytochrome CYP3A4 to said patient in unit dosage form, said metabolite being selected from the group consisting of:



ETM 305



ETM 204



ETM 775

or mixtures thereof.

<sup>22</sup>  
~~24~~. The method of claim 23, wherein the Ecteinascin 743 metabolite is designated herein as ETM-305.

09971852-100301

23


~~25~~. The method of Claim 23, wherein the Ecteinascin 743 metabolite is designated herein as ETM-204.

24


~~26~~. The method of Claim 23, wherein the Ecteinascin 743 metabolite is designated herein as ETM-775.

25


~~27~~. A method of treating mammalian lung carcinoma in patients in need of such treatment, said method comprising administering an effective amount of a metabolite of Ecteinascin 743 formed by human cytochrome CYP3A4 to said patient in unit dosage form, said metabolite being selected from the group consisting of:



ETM 305



ETM 204



ETM 775

or mixtures thereof.

26

~~28~~. The method of Claim 27, wherein the Ecteinascin 743 metabolite is designated herein as ETM-305.

A2  
cont

09971852-100301

27


29. The method of Claim 27, wherein the Ecteinasclidin 743 metabolite is designated herein as ETM-204.

28


30. The method of Claim 27, wherein the Ecteinasclidin 743 metabolite is designated herein as ETM-775.

29


31. A method of treating mammalian colon adenocarcinoma in patients in need of such treatment, said method comprising administering an effective amount of a metabolite of Ecteinasclidin 743 formed by human cytochrome CYP3A4 to said patient in unit dosage form, said metabolite being selected from the group consisting of:



ETM 305



ETM 204



ETM 775

or mixtures thereof.

09971852-100301

A2  
cont

30

32. The method of Claim 31, wherein the Ecteinasidin 743 metabolite is designated herein as ETM-305.

31


33. The method of Claim 31, wherein the Ecteinasidin 743 metabolite is designated herein as ETM-204.

32


34. The method of Claim 31, wherein the Ecteinasidin 743 metabolite is designated herein as ETM-775.

33


35. A method of treating mammalian malignant melanoma in patients in need of such treatment, said method comprising administering an effective amount of a metabolite of Ecteinasidin 743 formed by human cytochrome CYP3A4 to said patient in unit dosage form, said metabolite being selected from the group consisting of:



ETM 305



ETM 204



ETM 775

or mixtures thereof.

09971852-100301

34  
~~36~~. The method of claim 35, wherein the Ecteinasidin 743 metabolite is designated herein as ETM-305.

35  
~~37~~. The method of Claim 35, wherein the Ecteinasidin 743 metabolite is designated herein as ETM-204.

36  
~~38~~. The method of Claim 35, wherein the Ecteinasidin 743 metabolite is designated herein as ETM-775.

37  
~~40~~. A method of assaying the human cytochrome CYP3A4 metabolism of Ecteinasidin 743, comprising monitoring a test sample for the presence of one or more metabolites selected from the group consisting of ETM-204, ETM-305 and ETM-775.

09971852 100301